Equities Analysts Issue Forecasts for Clene FY2027 Earnings

Clene Inc. (NASDAQ:CLNN) – Investment analysts at Roth Capital increased their FY2027 earnings estimates for shares of Clene in a note issued to investors on Monday, March 24th. Roth Capital analyst J. Aschoff now expects that the company will post earnings per share of $6.41 for the year, up from their previous forecast of $6.30. The consensus estimate for Clene’s current full-year earnings is ($5.19) per share. Roth Capital also issued estimates for Clene’s FY2028 earnings at $9.04 EPS and FY2029 earnings at $12.47 EPS.

Clene (NASDAQ:CLNN) last posted its quarterly earnings results on Monday, March 24th. The company reported ($1.67) EPS for the quarter, missing analysts’ consensus estimates of ($1.21) by ($0.46). Clene had a negative net margin of 8,556.77% and a negative return on equity of 1,106.30%. The business had revenue of $0.09 million for the quarter, compared to the consensus estimate of $0.13 million.

CLNN has been the subject of a number of other reports. D. Boral Capital reaffirmed a “buy” rating and set a $23.00 price objective on shares of Clene in a report on Monday. HC Wainwright restated a “buy” rating and set a $31.00 target price on shares of Clene in a research report on Monday. Four research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Buy” and a consensus price target of $55.25.

Clene Trading Up 2.3 %

NASDAQ:CLNN opened at $3.54 on Wednesday. The stock has a 50-day moving average price of $4.49 and a 200 day moving average price of $4.88. The stock has a market capitalization of $29.47 million, a P/E ratio of -0.67 and a beta of 0.27. Clene has a 12-month low of $3.37 and a 12-month high of $9.20.

Hedge Funds Weigh In On Clene

Several institutional investors have recently added to or reduced their stakes in CLNN. Geode Capital Management LLC boosted its position in shares of Clene by 52.9% during the 4th quarter. Geode Capital Management LLC now owns 65,112 shares of the company’s stock valued at $346,000 after acquiring an additional 22,539 shares during the last quarter. Parsons Capital Management Inc. RI bought a new position in Clene during the fourth quarter valued at $194,000. Renaissance Technologies LLC purchased a new position in shares of Clene in the 4th quarter worth $96,000. SBI Securities Co. Ltd. bought a new stake in shares of Clene in the 4th quarter worth about $69,000. Finally, Fullcircle Wealth LLC purchased a new stake in shares of Clene during the 4th quarter valued at about $69,000. Hedge funds and other institutional investors own 23.28% of the company’s stock.

Clene Company Profile

Clene Inc, a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug candidate is CNM-Au8, which is being studied in various clinical trials, including a completed Phase 2 platform trial to evaluate the safety and efficacy of CNM-Au8 in patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; completed Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a second Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases.